Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Net Income (2023 - 2024)

Historic Net Income for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to -$14.6 million.

  • Contineum Therapeutics' Net Income fell 8747.59% to -$14.6 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$14.6 million, marking a year-over-year increase of 5892.79%. This contributed to the annual value of -$42.3 million for FY2024, which is 28599.47% down from last year.
  • Per Contineum Therapeutics' latest filing, its Net Income stood at -$14.6 million for Q4 2024, which was down 8747.59% from -$10.3 million recorded in Q3 2024.
  • Contineum Therapeutics' 5-year Net Income high stood at $41.6 million for Q2 2023, and its period low was -$14.6 million during Q4 2024.